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OBJECTIVE: Diabetic peripheral neuropathy (DPN) is a debili-
tating complication of diabetes and causes sensory symptoms
that impact health and functionality. The purpose of this study
was to test the hypothesis that there was a direct association
between the symptoms associated with DPN (SDPN), as mea-
sured by a new instrument the Neuropathy Total Symptom Score
(NTSS-6 [self administered]), and health-related utility as mea-
sured by the EQ5Dindex. The NTSS-6 provides a score of 0 to 3.66
in each of six domains. The score (range 0 to 21.96) is simply
summed with zero meaning no symptoms. METHODS: A postal
survey using various instruments including the NTSS-6 and the
EQ5D was mailed to subjects identiﬁed at random as having
either type-1 or Type-2 diabetes using the same methods as the
Health Outcomes Data Repository (HODaR). Univariate and
multivariate analysis were applied. This is a preliminary analy-
sis of the ﬁrst 604 returns. RESULTS: The mean age of respon-
dents was 64 years (IQR 55–73); 58% were male and the mean
duration of diabetes was 14 years (IQR 5–18). Of the 604
patients, 24% reported having no neuropathic symptoms. The
overall mean (SD) EQ5Dindex was 0.65 (0.33), and mean NTSS-
6 score 6.2 (median and IQR 4.33, 1.0–10.33). In univariate
analysis there was a direct association between the two instru-
ments (correlation coefﬁcient 0.57). Modeling the EQ5Dindex in
multiple linear regression analysis to account for confounding,
the NTSS-6 score was found to remain directly associated with
utility, whereby an increase of one unit on the NTSS-6 resulted
in as reduction in the EQ5Dindex of 0.029 units (p < 0.001). 
CONCLUSIONS: SDPN, as measured by the NTSS-6, were
directly associated with health-related utility. After accounting
for confounding factors, a unit change in the NTSS-6 was equiv-
alent to a change in utility that is considered to be clinically
meaningful.
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OBJECTIVE: To develop self-report questionnaires for physician
use in the evaluation of diabetic patient reluctance to start or
step up insulin regimens. METHODS: An Advisory Committee
(AC) was set up. It consisted of 3 diabetes specialists/endocri-
nologists, 1 behavioural psychiatrist and 2 general practitioners.
Three patient focus groups were formed from a pool of 23 type-
1 and 2 diabetic patients. Interviewees were asked to list fears,
constraints and beneﬁts associated with insulinization, injection
and insulin regimen step-up. After analysis of the focus groups,
a list of detailed concepts and two test questionnaires were devel-
oped and independently validated by the AC with content valid-
ity being assessed on 16 type-1 and 2 diabetic patients. Patients
completed the questionnaires before being systematically asked
to comment on the questionnaire as a whole and more speciﬁ-
cally on each element of the questionnaire. Questionnaires were
then redrafted and tested on 16 other patients. After analysis of
patient tests, a revised questionnaire was produced and validated
by the AC. RESULTS: Eleven elements (Insulinization: symbolic,
fears, constraints, beneﬁts, product physical characteristics.
Injection: symbolic, fears, constraints, positive points. Insulin
regimen intensiﬁcation: symbolic, fears) and 31 detailed concepts
were identiﬁed using the patient focus groups. Each test ques-
tionnaire contained 22 items (20 relating to insulin regimen start
or insulin regimen step-up plus 2 relating to inhaled insulin).
After initial cognitive debrieﬁng, one item was added, taking
each questionnaire to 23 items and response choices were 
signiﬁcantly modiﬁed in both questionnaires by the AC. After
second cognitive debrieﬁng 2 items were excluded from both
questionnaires by the AC. The pilot questionnaires therefore
included 21 items. CONCLUSION: These pilot questionnaires
may help physicians to assess the hurdles faced by diabetic
patients in starting or stepping up insulin regimens. The ques-
tionnaires are now undergoing item reduction, scoring and 
validation in two case-report studies.
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OBJECTIVE: To develop and evaluate a self-report clinical and
research adherence barrier survey designed to screen for speciﬁc
barriers to adherence across a spectrum of chronic conditions.
METHODS: Item generation and domain structures were based
on literature and expert opinion. Interviews with 33 patients
with asthma, diabetes, and heart failure were used to develop 47
Likert-type items. These were tested on the Web with 605
patients with asthma, diabetes, and depression. Factor analysis
was performed to identify conceptually similar item groupings;
and item validity in relation to a self-reported measure of adher-
ence, the distribution of item responses, and factor structure
were studied to select ﬁnal survey items. RESULTS: Twenty items
were retained based on correlation with validity criteria and clin-
ical relevance in the following domains: Lifestyle, Attitudes and
Beliefs, Help from Others, Talking with Health care Team, and
Difﬁculty Taking Medicines. A post hoc cut point dichotomizing
responses into “present” and “absent” was selected for each
item. The Barrier Total Index (BTI), the number of “barrier-
present” items, had an observed range from 0 to 18, a mean of
4.2 (±3.4), and good reliability (Cronbach’s alpha = 0.77). The
validity of the BTI with a self-report of a missed dose of medi-
cine in the past week was excellent. Patients who “missed” had
a mean of 6 barriers vs. 2.6 for those who did not (p < 0.0001).
CONCLUSION: The ASK Adherence Barrier Survey appears 
to be a useful tool to identify barriers to adherence in chronic
diseases. The survey can facilitate discussion of adherence 
and identify opportunities to implement barrier-speciﬁc 
interventions.
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Patient knowledge on own disease is recognised as key factor to
reach therapeutical goals. OBIECTIVE: To develop a question-
naire exploring patient preference on SBGM systems; to measure
patient satisfaction on medical information delivered by the hos-
pital health care personnel. METHODS: 454 NIDDM patients,
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between 40 and 80, were recruited by 40 diabetes clinics. A pilot
test-retest validity testing was performed on the same 10 respon-
dents following 2 weeks interval. Ten self-assessment items 
were developed for exploring preference on home glucometers;
3 items were developed for the following domains: needs for
better understanding on diabetes (yes/no); blood glucose self-
monitoring period (<6 months, >6 <18 months, >18 months <3
years, >3 <6 years, >6 years); access to diabetes clinics (regularly
scheduled—yes/no). The Pearson chi-square statistic for two-way
tables was used to test the association between variables; alpha
level of 0.05 was used in all analyses. RESULTS: Patients were
comparable for sex within each class of age (p = 0.670 / 40–
50 years; p = 0.152 / 50–60 years; p = 0.371 /60–70 years; p =
0.370 / 70–80 years). Unsatisﬁed (u) and satisﬁed (s) patients on
general information on diabetes respectively decreased and grew
with increasing age: 60.98% (u), 39.02% (s)/ 40–50 years; 52.14
% (u), 47.86% (s)/ 50–60 years; 45.77% (u), 54.23% (s)/ 60–70
years; 41.67% (u), 58.33% (s),/ 70–80 years (p = 0.05) without
correlating to SBGM period (p = 0.690). Frequency of accesses
to diabetes clinics increases with age from 40 to 80 (p = 0.004).
CONCLUSIONS: Patient perceived dissatisfaction with general
information on diabetes decreases with age and is independent
of SBGM period. Further studies have to be performed to eval-
uate if a better perceived knowledge of the disease can improve
adherence to the treatment and clinical outcomes.
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OBJECTIVES: To assess treatment satisfaction (TS) in a large
population of Type-2 diabetes subjects (T2DM) treated with
insulin glargine (GLAR). METHODS: The 24-week, multina-
tional AT.LANTUS study investigated TS with GLAR initiation
and titration (target FBG £5.5mmol/L) according to two algo-
rithms (Alg): Alg1 was physician based; Alg2 involved subject
self-titration. TS were assessed using the Diabetes Treatment 
Satisfaction Questionnaire status (DTSQs) and change (DTSQc).
Since blood glucose (BG) controls and stability (MODD, MAGE,
8-point BG proﬁles) improved signiﬁcantly, relationships with TS
were explored. RESULTS: TS was evaluated in a group of 
subjects from the eight countries in which the questionnaire was
validated, with 1289 subjects at baseline and 1023 subjects 
at endpoint. Mean baseline DTSQs scores were comparable
between Alg. (26.5 vs. 26.1) with signiﬁcant improvements at
endpoint (both +4.99; p < 0.001). Perceived hyperglycaemia sig-
niﬁcantly decreased (p < 0.001) with both Alg. TS evolution over
time (DTSQc) improved by +13.6 with both Alg. Perceived hypo-
glycaemia decreased in the DTSQc. There were signiﬁcant (p <
0.0001) correlations between fasting BG, mean 8-point BG and
evolution of TS scores and perceived hyperglycaemia. Evolution
of perceived hyperglycaemia was also associated with move-
ments towards BG stability (MAGE: p < 0.0001; MODD: p =
0.0004). A similar pattern of results was seen in the Type-1 pop-
ulation. CONCLUSIONS: This study provides one of the largest
assessments of TS to date and shows that aggressive titration of
GLAR is associated with signiﬁcantly improved TS. Self-titration
was associated with greater improvements in perceived hyper-
glycaemia versus physician-based titration. Perceived overall TS,
hyperglycaemia and hypoglycaemia at endpoint were all corre-
lated with movements towards BG control and stability, provid-
ing potential explanation as to why subjects feel better with
GLAR than their prior therapy.
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OBJECTIVE: To study the relationship of ARMD severity to
anxiety and depression in three European countries: France,
Germany and Italy. METHODS: Patients with wet ARMD 
were included in a retrospective cross-sectional survey. Socio-
demographic and medical data were collected during a visit by
a retina specialist. Anxiety and depression were assessed with the
Hospital Anxiety and Depression Scale (HADS). Two thresholds
were used to dichotomize visual acuity (VA): 20/40 for the best
eye (BE) and 20/200 for the worst eye (WE). Comparisons with
general population matched on age and gender were possible for
the German patients (Hinz, 2004). Analysis of variance was per-
formed to estimate the effect of each eye adjusted on age, gender
and country. RESULTS: A total of 360 patients were included.
The patients (40% male) averaged 77 years of age and 2.3 years
of disease duration. VA was 0.49 LogMAR on the BE the day
of the visit. In the German population, ARMD patient anxiety
score was higher than the general population both in male (5.4
vs. 4.7) and female (7.7 vs. 5.7). Some associations were found
between the severity of the disease and the depression score (BE
P < 0.004) and (WE P < 0.12) while no association was found
on the anxiety score. The prevalence of severe depression accord-
ing to HADS was 0% in the less severe (BE > = 20/40; WE > =
20/200) but 7.6% in the most severe group (BE < 20/40; WE <
20/200). CONCLUSION: Associations were found between
ARMD and depression and anxiety as measured by the HADS.
The severe depression prevalence rate increases when both eyes
are affected by the disease.
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OBJECTIVE: The control of daily IOP variations is a key driver
of visual ﬁeld protection. IOP is rarely measured during the night
in clinical trials. A model was used to predict nocturnal IOP
peaks from daytime measurements. METHODS: Two clinical
trials documenting IOP every 4 hours over several days were
pooled. Nocturnal IOP peak was deﬁned as the maximum value
observed at midnight and 4 AM and was related to diurnal mea-
sures (taken at 8:00, 12:00, 16:00 and 20:00). We employed
neural networks that included linear, radial basis, and multi-layer
perceptron (MLP) selected to minimize error and take into
account diversity. The probability of a nocturnal IOP peak > 17.5
mmHg was estimated. The neural network model was then
applied to data from a trial comparing timolol, travoprost and
latanoprost over 1 year. Drug comparisons were made using a
mixed linear model. RESULTS: 440 pairs of day and night IOP
measures were identiﬁed. A MLP (2:7:1) model was selected
based on sensitivity and speciﬁcity which were both close to one.
The analysis of the MLP output showed afternoon IOPs were
stronger predictors of night peaks than morning IOPs. Applying
